Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov Sells 10,000 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $5.25, for a total value of $52,500.00. Following the completion of the transaction, the director now directly owns 61,156 shares of the company’s stock, valued at approximately $321,069. This represents a 14.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Rosty Raykov also recently made the following trade(s):

• On Wednesday, March 5th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.79, for a total value of $67,900.00.
• On Wednesday, February 5th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.66, for a total transaction of $66,600.00.
• On Monday, January 6th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.08, for a total transaction of $60,800.00.

Fennec Pharmaceuticals Stock Down 6.1 %

Shares of NASDAQ:FENC opened at $5.25 on Friday. The firm has a market capitalization of $144.84 million, a PE ratio of -52.49 and a beta of 0.32. The company has a 50-day moving average price of $6.51 and a two-hundred day moving average price of $5.72. Fennec Pharmaceuticals Inc has a twelve month low of $3.96 and a twelve month high of $11.11.

Institutional Trading of Fennec Pharmaceuticals

Institutional investors have recently modified their holdings of the business. State Street Corp raised its holdings in Fennec Pharmaceuticals by 2.2% during the 3rd quarter. State Street Corp now owns 328,259 shares of the company’s stock valued at $1,641,000 after acquiring an additional 7,053 shares during the period. Barclays PLC grew its position in shares of Fennec Pharmaceuticals by 274.3% in the third quarter. Barclays PLC now owns 31,319 shares of the company’s stock valued at $157,000 after purchasing an additional 22,951 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Fennec Pharmaceuticals by 18.7% during the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock valued at $74,000 after purchasing an additional 2,330 shares during the period. Rhumbline Advisers lifted its holdings in Fennec Pharmaceuticals by 12.9% during the 4th quarter. Rhumbline Advisers now owns 34,299 shares of the company’s stock worth $217,000 after purchasing an additional 3,911 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Fennec Pharmaceuticals by 10.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 61,146 shares of the company’s stock worth $386,000 after purchasing an additional 5,694 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on FENC shares. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a report on Tuesday, March 11th. Wedbush restated an “outperform” rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a research note on Monday, March 10th.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.